Citations

Showing 10 of 108094 citations.

Adult Presentation of Ornithine Transcarbamylase Deficiency: 2 Illustrative Cases of Phenotypic Variability and Literature Review
Pizzi, Michael , Alejos, David , Hasan, Tasneem F. , Krishnaiengar, Suparna, Pizzi, Michael A. , Atwal, Paldeep S , Freeman, William D.

Mayo Clinic

The Neurohospitalist | March 27, 2018 | Volume: 9 | Issue: 1 | Pages: 30-36

10.1177/1941874418764817 | PMID 30671162 Get It

Ornithine transcarbamylase (OTC) deficiency is an X-linked recessive disorder that usually presents in the neonatal period. Late-onset presentation of OTC can cause mild to severe symptoms. We describe laboratory and clinical findings of late-onset presentations of OTC deficiency. We conducted a literature search using search terms “ornithine transcarbamylase deficiency,” “late onset presentation,” and “hyperammonemia” from January 1, 1987, to December 31, 2016, was performed. Only papers published in English were included. We searched on PubMed, MEDLINE, and Google Scholar. We also present 2 OTC deficiency cases. A total of 30 adult cases had late-onset presentation of OTC deficiency reported. The majority were women (57%) with a median age of 37 years. The median level of ammonia was 308 mmol/L and the mortality rate was 30%. Our case 1 was a 40-year-old woman who succumbed to neurologic complications after a hyperammonemia crisis following an increased protein intake. Our case 2 was a 43-year-old woman with seizures associated with increased ammonia levels. Our 2 case reports show the wide phenotypic variability and severity in late-onset presentation of OTC ranging from seizures to cerebral herniation. Our literature review is the first to detail published laboratory and neurologic sequelae of late-onset OTC deficiency.
The Determinants of Palliative Care Use in Patients With Colorectal Cancer: A National Study
Osagiede, Osayande , Spaulding, Aaron , Frank, Ryan D. , Merchea, Amit , Mathis, Kellie L. , Parker, Alexander S. , Colibaseanu, Dorin T, Osagiede, Osayande , Spaulding, Aaron C. , Spaulding, Aaron , Colibaseanu, Dorin , Ailawadhi, Sikander

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | March 27, 2018 | Volume: 35 | Issue: 10 | Pages: 1295-1303

10.1177/1049909118765092 | PMID 29580075 Get It

Background: Palliative care is associated with improved survival and quality of life, but its use among patients with colorectal cancer varies nationwide and the determinants of those variations are not clear. Objective: To determine the factors associated with palliative care use among patients who died of colorectal cancer. Methods: Deceased patients treated for colorectal cancer (2004-2013) were identified within the National Cancer Database. Multivariable logistic regression was used to evaluate patient and institutional characteristics associated with palliative care use. Patients were classified based on their length of survival (<6 months, 6-24 months, and 24+ months) to provide timing context. Results: A total of 287 923 patients were analyzed. Overall, 4.3% of the patients received palliative care. Patients who received palliative care were more likely to be younger, recently diagnosed, treated at academic hospitals, and have stage IV disease. Patients living in Mountain and Pacific regions had higher odds of palliative care receipt than those in the East Coast. Patients without insurance had higher odds of palliative care if they survived <24 months. Insurance coverage through Medicaid was associated with increased palliative care use among patients who survived 6 to 24 months. Patients who survived <6 months and lived >9 miles from the institution received more palliative care. Conclusion: Palliative care use among patients with colorectal cancer is associated with a younger age, a more recent year of diagnosis, insurance status, academic hospitals, and living in Mountain and Pacific regions.
Cardiac Tamponade as the Initial Presentation of Acute Myeloid Leukemia: A Case Report with Review of the Literature
Karmo, Dillon , Hafeez, Adam , Halalau, Alexandra , Yadav, Siddhartha , Yadav, Siddhartha , Halalau, Alexandra

Mayo Clinic

Case Reports in Oncological Medicine | March 26, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-3

10.1155/2018/8201917 | PMID 29780652 Get It

Acute myeloid leukemia (AML) is a complex disease with a variety of presentations. A large pericardial effusion is rare, occurring in less than 0.5% of all patients with AML prior to treatment. A 34-year-old male presented with dyspnea, malaise, and weight loss. On physical exam, he was noted to be hypoxic, tachypneic, tachycardic, and hypotensive. He had cervical lymphadenopathy and jugular venous distention. His WBC count was 110 bil/L with 33% blasts. Bone marrow biopsy confirmed AML with 60% blasts. Leukemic cells were also seen in the cerebrospinal fluid on lumbar puncture. An echocardiogram revealed a large pericardial effusion causing tamponade. He underwent emergent pericardiocentesis, and malignant cells were present in the pericardial fluid. Induction therapy with standard dose cytarabine and daunorubicin was initiated, and bone marrow biopsy 14 days later showed no residual AML. This case demonstrates the importance of a thorough evaluation of each organ system when caring for a patient with AML.
Incorporating Cystatin C to Predict Methotrexate Elimination in Patients with CNS Lymphoma and Suspicious Renal Function
Barreto, Jason N. , McClanahan, Allison L., Thompson, Carrie A. , Frazee, Erin N. , Frazee, Erin N , Rule, Andrew D.

Mayo Clinic

Case Reports in Hematology | March 26, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-5

10.1155/2018/7169897 | PMID 29780646 Get It

High-dose methotrexate (MTX; ≥1 g/m2) is a renally eliminated and nephrotoxic first-line therapy for central nervous system (CNS) lymphoma. Creatinine-based estimation of renal function is the recommended approach to dosing MTX in these cases, but nonrenal determinants of creatinine production and elimination in cancer patients such as malnutrition and cachexia lead to overestimation of glomerular filtration rate (GFR) by this method and a heightened risk for drug toxicity. Serum cystatin C is one of the first readily available, relatively inexpensive, endogenous biomarkers to emerge as a practical adjunct to creatinine for estimation of renal function for drug dosing. In this report, we describe two cases where cystatin C was used in conjunction with creatinine to inform MTX dosing for CNS lymphoma. In both cases, the estimated GFR was nearly 40% lower with the combination of the two biomarkers compared to creatinine-only estimates. Empiric MTX dose reductions as a product of these results likely spared the patients sustained exposure to toxic drug concentrations and facilitated earlier administration of supportive care interventions. Further prospective investigations with validated dosing regimens including cystatin C are warranted for high-dose MTX.
Cochlear Implantation in Charcot-Marie-Tooth Disease: Case Report and Review of the Literature
Anzalone, C. Lane , Nuhanovic, Sarah, Olund, Amy P., Carlson, Matthew L.

Mayo Clinic

Case Reports in Medicine | March 26, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-3

10.1155/2018/1760978 | PMID 29780422 Get It

Introduction. Charcot-Marie-Tooth (CMT) disease is a peripheral hereditary neuropathy associated with motor and sensory impairment and can result in profound sensorineural hearing loss (SNHL). Currently, the role of cochlear implantation in the setting of CMT and other progressive peripheral neurodegenerative disorders is not well established. Methods. Case report and review of the English literature. Results. A 70-year-old male with CMT was referred for evaluation of progressive asymmetric SNHL and reported a 15-year duration of deafness involving the left ear. Audiometric testing confirmed profound SNHL in the left ear, while the right ear exhibited moderate-to-severe SNHL. Left-sided cochlear implantation was performed using a conventional length lateral wall electrode. Intraoperative device testing found normal impedance levels throughout the array; however, electrically evoked auditory potentials were absent on all electrodes. Upon initial activation 3 weeks after surgery, the patient reported excellent access to sound in the cochlear implant-only condition. He has made good progress at each subsequent visit; speech perception testing after seven months showed improvement from 0% to 32% on AzBio sentence and 53% on CNC phoneme testing in the cochlear implant-only condition. Conclusion. We report the third case of cochlear implantation in a patient with CMT. SNHL in CMT is hypothesized to result from disruption of synchronous activity of the cochlear nerve. In patients with CMT, cochlear implantation may reconstitute synchronous neural activity by way of supraphysiological electrical stimulation. Our results corroborate two earlier reports that cochlear implantation is a viable option for rehabilitation of SNHL in this unique subset of patients.
Quantitative Anatomic Analysis of the Medial Ulnar Collateral Ligament Complex of the Elbow
Jahandar, Hamidreza, Sinatro, Alec M., Imhauser, Carl W. , Altchek, David W. , Camp, Christopher L. , Dines, Joshua S.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | March 26, 2018 | Volume: 6 | Issue: 3 | Pages: No page available

10.1177/2325967118762751 | PMID 29637082 Get It

Background: A more detailed assessment of the anatomy of the entire medial ulnar collateral ligament complex (MUCLC) is desired as the rate of medial elbow reconstruction surgery continues to rise. Purpose: To quantify the anatomy of the MUCLC, including the anterior bundle (AB), posterior bundle (PB), and transverse ligament (TL). Study Design: Descriptive laboratory study. Methods: Ten unpaired, fresh-frozen cadaveric elbows underwent 3-dimensional (3D) digitization and computed tomography with 3D reconstruction. Ligament footprint areas and geometries, distances to key bony landmarks, and isometry were determined. A surgeon digitized the visual center of each footprint, and this location was compared with the geometric centroid calculated from the outline of the digitized footprint. Results: The mean surface area of the AB was 324.2 mm 2 , with an origin footprint of 32.3 mm 2 and an elongated insertional footprint of 187.6 mm 2 (length, 29.7 mm). The mean area of the PB was 116.6 mm 2 (origin, 25.9 mm 2 ; insertion, 15.8 mm 2 ), and the mean surface area of the TL was 134.5 mm 2 (origin, 21.2 mm 2 ; insertion, 16.7 mm 2 ). The geometric centroids of all footprints could be predicted within 0.8 to 1.3 mm, with the exception of the AB insertion centroid, which was 7.6 mm distal to the perceived center at the apex of the sublime tubercle. While the PB remained relatively isometric from 0° to 90° of flexion ( P = .606), the AB lengthened by 2.2 mm ( P < .001). Conclusion: Contrary to several historical reports, the insertional footprint of the AB was larger, elongated, and tapered. The TL demonstrated a previously unrecognized expansive soft tissue insertion directly onto the AB, and additional analysis of the biomechanical contribution of this structure is needed. Clinical Relevance: These findings may serve as a foundation for future study of the MUCLC and help refine current surgical reconstruction techniques.
Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter‐Defibrillators in the Cardiovascular Research Network
Greenlee, Robert T. , Go, Alan S. , Peterson, Pamela N., Gaber, Charles , Garcia‐Montilla, Romel , Glenn, Karen A., Gupta, Nigel, Gurwitz, Jerry H. , Hammill, Stephen C., Hayes, John J., Kadish, Alan H. , Magid, David J. , McManus, David D. , Multerer, Deborah, Powers, J. David , Reifler, Liza M. , Schuger, Claudio , Sharma, Param , Smith, David H. , Suits, Mary, Sung, Sue Hee, Varosy, Paul D. , Vidaillet, Humberto, Masoudi, Frederick A. , Peterson, Pamela N. , Cassidy‐Bushrow, Andrea E. , Reynolds, Kristi

Mayo Clinic

Journal of the American Heart Association | March 26, 2018 | Volume: 7 | Issue: 7 | Pages: No page available

10.1161/jaha.117.008292 | PMID 29581222 Get It

Background Primary prevention implantable cardioverter‐defibrillators (ICDs) reduce mortality in selected patients with left ventricular systolic dysfunction by delivering therapies (antitachycardia pacing or shocks) to terminate potentially lethal arrhythmias; inappropriate therapies also occur. We assessed device therapies among adults receiving primary prevention ICDs in 7 healthcare systems. Methods and Results We linked medical record data, adjudicated device therapies, and the National Cardiovascular Data Registry ICD Registry. Survival analysis evaluated therapy probability and predictors after ICD implant from 2006 to 2009, with attention to Centers for Medicare and Medicaid Services Coverage With Evidence Development subgroups: left ventricular ejection fraction, 31% to 35%; nonischemic cardiomyopathy <9 months’ duration; and New York Heart Association class IV heart failure with cardiac resynchronization therapy defibrillator. Among 2540 patients, 35% were <65 years old, 26% were women, and 59% were white. During 27 (median) months, 738 (29%) received ≥1 therapy. Three‐year therapy risk was 36% (appropriate, 24%; inappropriate, 12%). Appropriate therapy was more common in men (adjusted hazard ratio [HR], 1.84; 95% confidence interval [CI], 1.43–2.35). Inappropriate therapy was more common in patients with atrial fibrillation (adjusted HR, 2.20; 95% CI, 1.68–2.87), but less common among patients ≥65 years old versus younger (adjusted HR, 0.72; 95% CI, 0.54–0.95) and in recent implants (eg, in 2009 versus 2006; adjusted HR, 0.66; 95% CI, 0.46–0.95). In Centers for Medicare and Medicaid Services Coverage With Evidence Development analysis, inappropriate therapy was less common with cardiac resynchronization therapy defibrillator versus single chamber (adjusted HR, 0.55; 95% CI, 0.36–0.84); therapy risk did not otherwise differ for Centers for Medicare and Medicaid Services Coverage With Evidence Development subgroups. Conclusions In this community cohort of primary prevention patients receiving ICD, therapy delivery varied across demographic and clinical characteristics, but did not differ meaningfully for Centers for Medicare and Medicaid Services Coverage With Evidence Development subgroups.
Prognostic Performance of Heart Rate Recovery on an Exercise Test in a Primary Prevention Population
Sydó, Tibor, Carta, Karina Auristela Gonzalez, Hussain, Nasir , Farooq, Shausha, Murphy, Joseph G. , Allison, Thomas G. , Sydó, Nóra, Gonzalez Carta, Karina A, Sydó, Nóra , Merkely, Béla , López-Jiménez, Francisco

Mayo Clinic

Journal of the American Heart Association | March 26, 2018 | Volume: 7 | Issue: 7 | Pages: No page available

10.1161/jaha.117.008143 | PMID 29581219 Get It

Background Heart rate ( HR ) recovery has been investigated in specific patient cohorts, but there is less information about the role of HR recovery in general populations. We investigated whether HR recovery has long‐term prognostic significance in primary prevention. Methods and Results Exercise tests performed between 1993 and 2010 on patients aged 30 to 79 years without cardiovascular disease were included. Mortality was determined from Mayo Clinic records and Minnesota Death Index. Total, cardiovascular , and non‐cardiovascular mortality was reported according to HR recovery <13 bpm using Cox regression. 19 551 patients were included, 6756 women (35%), age 51±10 years. There were 1271 deaths over follow‐up of 12±5 years. HR recovery declined after age 60, and was also lower according to diabetes mellitus, hypertension, obesity, current smoking, and poor cardiorespiratory fitness but not sex or β‐blockers. Adjusting for these factors, abnormal HR recovery was a significant predictor of total (hazard ratio [95% confidence interval]=1.56 [1.384–1.77]), cardiovascular (1.95 [1.57–2.42]), and non‐cardiovascular death (1.41 [1.22–1.64]). Hazard ratios for cardiovascular death according to abnormal HR recovery were significant in all age groups (30–59, 60–69, 70–79), in both sexes, in patients with and without hypertension, obesity, and diabetes mellitus, but not in patients taking β‐blockers, current smokers, and patients with normal cardiorespiratory fitness. Conclusions HR recovery is a powerful prognostic factor predicting total, cardiovascular, and non‐cardiovascular death in a primary prevention cohort. It performs consistently well according to sex, age, obesity, hypertension, and diabetes mellitus but shows diminished utility in patients taking β‐blockers, current smokers, and patients with normal cardiorespiratory fitness.
Cytomorphology and sonographic features of ectopic thymic tissue diagnosed in paediatric FNA biopsies
Escobar, Fernando , Craig, Fiona E. , Simons, Jeffrey S. , Viswanathan, Pushpa, Yilmaz, S. , Monaco, Sara E. , Monaco, S E , Pantanowitz, Liron , Picarsic, Jennifer , Simons, J. P.

Mayo Clinic

Cytopathology | March 26, 2018 | Volume: 29 | Issue: 3 | Pages: 241-246

10.1111/cyt.12529 | PMID 29577488 Get It

IntroductionEctopic thymic tissue can arise as an asymptomatic neck mass, which may be detected on imaging studies. The aim of this study was to determine the incidence of ectopic thymic tissue in paediatric FNAs and to the correlate clinical, radiological and cytomorphological findings.MethodsFNAs in children with neck and mediastinal lesions performed between January 2012 and July 2016 were reviewed for cases of ectopic thymus. These were then evaluated and correlated with the cytology findings.ResultsOf 739 FNAs, 13 (1.8%) cases from 11 patients showed ectopic thymic tissue. The targeted lesions were in the thyroid (n = 7), submandibular region (n = 1), superior mediastinum (n = 1) and paratracheal region (n = 1). The most common indication was for microcalcifications concerning for papillary thyroid carcinoma on ultrasound (n = 6). Imaging findings included fusiform lesions with linear and punctuate bright echoes. The cytology evaluation showed small lymphocytes with discohesive epithelioid cells in most cases, and proteinaceous fluid in the cystic case. There were rare macrophages and Hassall's corpuscles. Flow cytometry and/or immunostains were performed in all cases, supporting thymic origin.ConclusionEctopic thymic tissue is rarely present as a neck mass or thyroid nodule on FNA biopsy. The ultrasound imaging findings reveal a well‐defined fusiform lesion with punctate bright echoes that could be misinterpreted as papillary thyroid carcinoma. The aspirates show a small lymphoid population, immunophenotypically compatible with thymic T‐cells, in addition to scattered epithelial cells. Therefore, knowledge of the typical ultrasonographic and cytopathological features can help make a definitive diagnosis and avoid more invasive procedures in paediatric patients.
Perioperative Management of Hyperlipidemia Medications
Renew, J. Ross , Renew, Johnathan Ross

Mayo Clinic

Current Clinical Pharmacology | March 26, 2018 | Volume: 12 | Issue: 3 | Pages: 152-156

10.2174/1574884712666171108103325 | PMID 29119935 Get It